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ABSTRACT
Background: Germ cell tumours are uniquely associated with the gametogenic tissues of males and females. A feature of these can-
cers is that they can express genes that are normally tightly restricted to meiotic cells. This aberrant gene expression has been used
as an indicator that these cancer cells are attempting a programmed germ line event, meiotic entry. However, work in non-germ cell
cancers has also indicated that meiotic genes can become aberrantly activated in a wide range of cancer types and indeed provide
functions that serve as oncogenic drivers. Here, we review the activation of meiotic factors in cancers and explore commonalities
between meiotic gene activation in germ cell and non-germ cell cancers.
Objectives: The objectives of this review are to highlight key questions relating to meiotic gene activation in germ cell tumours and
to offer possible interpretations as to the biological relevance in this unique cancer type.
Materials and Methods: PubMed and the GEPIA database were searched for papers in English and for cancer gene expression data,
respectively.
Results: We provide a brief overview of meiotic progression, with a focus on the unique mechanisms of reductional chromosome
segregation in meiosis I. We then offer detailed insight into the role of meiotic chromosome regulators in non-germ cell cancers and
extend this to provide an overview of how this might relate to germ cell tumours.
Conclusions: We propose that meiotic gene activation in germ cell tumours might not indicate an unscheduled attempt to enter a
full meiotic programme. Rather, it might simply reflect either aberrant activation of a subset of meiotic genes, with little or no biolog-
ical relevance, or aberrant activation of a subset of meiotic genes as positive tumour evolutionary/oncogenic drivers. These postu-
lates provide the provocation for further studies in this emerging field.
INTRODUCTION
Human gametogenesis generates spermatozoa and oocytes
that may ultimately fuse to form a zygote. Whilst the human
male and female gametogenic programmes differ considerably
in their timing and context, with a defined number of oocytes
generated only in the foetal ovaries and spermatozoa produced
continually in the testis of sexually competent, post-pubescent
males, both share the requirement to undergo a reduction chro-
mosomal segregation from the diploid state during meiosis
(Spiller et al., 2012; Feng et al., 2014; Griswold, 2016; Nagaoka &
Saitou, 2017; Sanders & Jones, 2018). The extent to which male
and female meiosis differs in humans has undergone relatively
little investigation, mostly due to technical/ethical issues
and limitations of reconstitution of mammalian gametogenic
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programmes in vitro. Given this, much of what is known about
the regulation of meiotic initiation and the mechanisms of mei-
otic chromosomes segregation comes from studies in model
eukaryotes, particularly murine systems, with a greater emphasis
on spermatogenesis (Griswold, 2016). Thus, much of our under-
standing of these processes is extrapolative in nature. Despite
these constraints, it is becoming clear that activation of meiotic
genes (and other germ line genes) occurs during oncogenesis
and that these genes provide functions for both initiation and
maintenance of the cancerous state in a range of cancer types
(Simpson et al., 2005; Fratta et al., 2011; Rousseaux et al., 2013;
Lafta et al., 2014; McFarlane et al., 2014, 2015; Whitehurst, 2014;
Nielsen & Gjerstorff, 2016). It is an emerging possibility that mei-
otic deregulation is a feature of germ cell (GC) tumours (for
example, see Jørgensen et al., 2013). The extent of the contribu-
tion to distinct aspects of oncogenesis by meiotic genes, whose
expression is normally restricted to gametogenesis, has only
undergone limited scrutiny to date. Moreover, their role in GC
tumour development and progression is complicated by the fact
that GC tumours are associated with the gametogenic tissues.
So, distinguishing aberrant activation of one or more meiotic
and germ line genes from attempted inappropriate entry into a
full meiotic programme possesses important, yet challenging
questions; for example:
• Does activation of meiotic genes in GC tumours indicate that
these cells are attempting a true germ line meiotic entry?
• Can analysis of expression of a subset of selected meiotic
genes be used as markers to indicate a bona fide meiotic entry
signalling network?
• Or, are these genes being activated independently of a full
meiotic entry programme? And if so, what regulates their
activation?
• Do these genes provide meiotic-like functions that contribute
to oncogenic maintenance, progression and therapeutic resis-
tance in GC tumours, as they do in other cancer types?
Here, we provide insight from recent studies on the role of
meiotic genes in a wide range of cancers. Whilst limited data
negate addressing the emerging questions associated with GC
cancers, we aim to offer the context in which these questions
should be embedded.
MEIOSIS: A BRIEF OVERVIEW
After arrival of primordial germ cells (PGCs) at the developing
gonad, the cells undergo extensive epigenetic reprogramming,
and development is directed either towards ovaries or testis
depending on the presence or absence of a functioning SRY gene,
which is normally located on the Y chromosome (Witchel, 2018).
There are pronounced differences in regulation and timing of
gametogenesis in females and males, but both require a meiotic
chromosome segregation programme to drive haploidization; in
the foetal ovaries, a defined number of oocytes enter prophase I
of meiosis I, whereas in the foetal testes, meiotic entry is inhib-
ited until puberty and spermatozoa are subsequently produced
continually (Jørgensen & Rajpert-De Meyts, 2014). However, dur-
ing the general process of meiosis diploid germ line progenitor
cells undergo a single round of pre-meiotic DNA replication fol-
lowed by two chromosome segregation events, meiosis I (reduc-
tional) and meiosis II (equational), ultimately creating haploid
gametes (Zickler & Kleckner, 1999) (Fig. 1 shows a schematic of
the meiosis I reductional segregation).
The hormonal cues and signalling cascades for human meiotic
entry are poorly delineated, but it is now thought that meiotic
entry is initiated by retinoic acid (RA) coupled with STRA8 (Stim-
ulated by Retinoic Acid 8) gene expression (Feng et al., 2014; Ma
et al., 2018). In foetal ovaries, RA and STRA8 induce the meiotic
initiation programme, whereas the entry into meiosis in males is
thought to be inhibited by the expression of the CYP26B gene,
which encodes a RA-degrading enzyme. Moreover, a number of
important regulatory players have been identified in recent
years, including DAZL, FGF9, NANOS2/3 and DMRT1 (Jorgensen
et al., 2012; Spiller et al., 2012; Zhang & Zarkower, 2017).
During pre-meiotic DNA replication, newly formed sister
chromatids remain connected via the actions of a ring structure
termed cohesin that encircles both sister chromatids (Ishiguro,
2018) (Fig. 1A,B). Following this, the homologous chromosomes
undergo a dramatic juxtapositioning to initiate pairing and
alignment. During this period, a specific meiotic recombination
programme is initiated by the generation of DNA double-
stranded breaks (DSBs) in one chromatid of one of the homo-
logues (Humphryes & Hochwagen, 2014; Hunter, 2015; Gray &
Cohen, 2016) (Fig. 1B). This is initiated by a topoisomerase VI-
like complex, which consists of SPO11 and TOPOVIBL
(C11orf80) (Robert et al., 2016) (Fig. 2B,C). The SPO11 subunit
remains covalently bound to the 50 end of each side of the break,
both of which are subsequently resected to generate a stretch of
single-stranded DNA with a free 30 end (Fig. 2C,D). This provides
the substrates for the recombinase RAD51 and its meiosis-speci-
fic paralogue DMC1, enabling them to mediate the strand inva-
sion of a homologous duplex (Hunter, 2015) (Fig. 2E).
Meiotic recombination is not initiated uniformly throughout
the genome, with some loci being more prone to serve as recom-
bination initiation sites (Fig. 1B); these are referred to as meiotic
recombination hot spots, and there are regions where the chro-
matin takes on a more open, permissive configuration enabling
the SPO11-TOPOVIBL complex to access the DNA (Wahls &
Davidson, 2010; Tock & Henderson, 2018). Hot spot chromatin
activation is driven by meiosis-specific factors such as the zinc
finger histone methyltransferase, PRDM9 (Grey et al., 2018; Pai-
gen & Petkov, 2018) (Fig. 2A).
Importantly, unlike mitosis, where DSB repair mediated by
homologous recombination is mostly channelled down an inter-
sister chromatid route, the repair of programmed meiotic DSBs
occurs with a bias to inter-homologue strand invasion mediated
by an additional group of meiosis-specific factors, which include
HOP2 (PSMC3IP)-MND1 (Hunter, 2015) (Figs 1B,C and 2E).
Some recombination intermediates generated via this inter-
homologue route dissociate and do not progress to make chro-
mosome crossovers; others, however, ultimately form Holliday
junctions and can be processed to generate chiasmata structures
in the bivalent and the chromosomal crossovers that serve as a
major evolutionary driver (Hunter, 2015) (Fig. 1D).
As the recombination-dependent bivalents align on the meta-
phase I plate, the centromeres of sister chromatids form
monopolar spindle associations that are unique to meiosis I and
are required to drive the reductional segregation at this stage
(Zickler & Kleckner, 1999) (Fig. 1D,E). Loss of sister cohesion in
the arm regions of chromosomes, but not the centromeric
regions, occurs on entry into anaphase I permitting reductional
segregation, as this disrupts the bivalent, yet permits inter-sister
cohesion to be maintained at the centromeres (Fig. 1E). During
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meiosis II, centromeric cohesion is broken down and an equa-
tional segregation ensues (Ishiguro, 2018).
ACTIVATION OF MEIOTIC CHROMOSOME REGULATORS
IN NON-GERM CELL CANCERS
Germ line gene activation, including meiotic genes, appears to
be a common feature in a range of human neoplastic conditions
(McFarlane et al., 2014, 2015; McFarlane & Wakeman, 2017). If
applied to mitotically proliferating cells, the specific molecular
mechanisms driving reductional segregation in gametogenic
meiosis I could be considered to be deleterious and potentially
highly oncogenic. Examples include the genesis of DSBs, the
modulation of inter-homologue repair of DSBs that could drive
loss of heterozygosity, the alteration of the transcriptional land-
scape, the epigenetic activation of recombination hot spot loci
and the monopolar orientation of sister chromatid centromeres.
Evidence is starting to emerge that meiosis-like activities medi-
ated by unscheduled activation of meiotic genes do indeed con-
tribute to oncogenesis, but there are some unexpected ways in
which these activities make their contribution, challenging intu-
itive hypotheses for roles of meiotic gene activity in cancer cells
(McFarlane & Wakeman, 2017). This is particularly apparent
when applied to GC tumours where activation of meiosis-speci-
fic genes might be taken to imply meiotically primed cells are
attempting a programmed entry into meiosis, albeit a flawed
one (Jørgensen et al., 2013). This might indeed be the case, but
the evidence from studies of oncogenic roles in other cancers
and model systems should engender consideration of other pos-
sibilities for the causes and roles of meiotic gene activation in
GC tumours.
The meiotic recombination initiators in cancer
Cancer/testis (CT) genes are a class of gene that has expres-
sion normally restricted to the testis of adult males, but which
become active in some, if not even all cancers (Simpson et al.,
2005; Whitehurst, 2014; Gibbs & Whitehurst, 2018). SPO11, the
key mediator of meiotic DSB formation, and PRDM9, the histone
methyltransferase activator of a subgroup of meiotic recombina-
tion hotspots, are both encoded for by meiosis-specific genes
that have been reported to be CT genes (Koslowski et al., 2002;
Feichtinger et al., 2012). To date, no direct evidence has been
put forward to indicate human SPO11 has oncogenic function
(s), but remarkable insight into a potential oncogenic role comes
from seminal work in Drosophila melanogaster (Janic et al.,
2010; Rossi et al., 2017). It has been demonstrated that the for-
mation of D. melanogaster larval brain tumours can be gener-
ated when lava carrying temperature-sensitive alleles of the l(3)
mbt gene are shifted to the non-permissive condition (Janic
et al., 2010). Transcriptional profiling of these tumours demon-
strated that they activated a large number of germ line genes,
some of which were required for tumour formation (Janic et al.,
2010; Rossi et al., 2017). Interestingly, activation of a similar
gene profile is also observed in a number of human cancers
(Feichtinger et al., 2014). Two of the fly genes required for l(3)
Pre-meioc DNA
replicaon Prophase I Anaphase IMetaphase I
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Figure 1 Schematic of chromosome dynamics during the reductional segregation of meiosis I. The progression from left to right shows a pair of homolo-
gous chromosomes (green and blue) undergoing pre-meiotic DNA replication (A), through to anaphase I (E). (A) During pre-meiotic DNA replication, cohe-
sion is established between sister chromatids (yellow dots). This is mediated by a ring-shaped complex termed cohesin. In meiosis, some chromosomal
cohesin complexes contain meiosis-specific subunits, some of which can be activated during oncogenesis. Cohesin is enriched at the centromeric regions
(denoted by the starburst shapes). (B) Early in prophase I, homologous chromosomes align with one another and meiotic recombination is initiated by the
generation programmed of DNA double-strand breaks (DSBs). DSBs occur predominantly at specific genomic loci termed hot spots (illustrated by the red
arrow). Meiosis-specific mechanisms direct homologous recombination to repair the DSBs preferentially via an inter-homologue route, as opposed to an
inter-sister chromatid route (red arrows). (C) This inter-homologue recombination results in the formation of stable homologous recombination intermedi-
ates (illustrated by the constriction points) and the formation of a bivalent. A continuous proteinaceous ladder-like structure forms between the synapsed
homologues called the synaptonemal complex (SC). The SC comprises axial structures associated with the cohesin complex (magenta lines) on each homo-
logue and these are conjoined by a central element making the rungs of the ‘ladder’ (horizontal grey lines). The SC comprises many meiosis-specific factors,
some of which can become activated during oncogenesis, such as SYCP3, a component of the axial structures of the SC. (D) Late in prophase I, the SC starts
to break down and homologous recombination intermediates (Holliday junctions) dissociate to give an obligate crossover in each arm of the bivalent. (D–E)
Cells transition through metaphase I during which time the spindle forms monopolar kinetochore associations with the centromeres to give a reductional
segregation. Monopolarity is dependent on meiosis-specific cohesin subunit REC8. The metaphase I-to-anaphase I transition requires cleavage of sister chro-
matid cohesion in the arms of the bivalent, which releases crossed over chromosome arms. Centromeric cohesion is maintained in metaphase I enabling the
monopolar migration of the sister centromeres (E). Sister centromere cohesion is maintained to orchestrate inter-sister associations at metaphase II, where
sister centromeres now form bipolar spindle associations permitting an equational segregation during anaphase II (not shown).
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mbt tumour formation were mei-W68 and mei-P22, the ortho-
logues of human SPO11 and TOPOVIBL, respectively (Rossi
et al., 2017). This work was extended to demonstrate that the
oncogenic role of the D. melanogaster orthologue of SPO11
(Mei-W68) for tumour formation could be suppressed, to some
degree, by ionizing irradiation, suggesting that the function that
Mei-W68 mediates is DSB-associated (although this remains to
be fully determined as irradiation does activate a small cohort of
additional genes which could potentially suppress the need for a
non-DSB-forming function of Mei-W68) (Rossi et al., 2017).
The meiosis-specific histone methyltransferase gene PRDM9
has also been reported to be activated in cancers (Feichtinger
et al., 2012). The murine orthologue of PRDM9, Meisetz, not only
serves as a meiotic recombination activator (Fig. 2A), but also
serves as a transcriptional activator for a specific subgroup of
genes in meiosis (Hayashi et al., 2005). Overexpression of human
PRDM9 in HEK293T cells can also activate the upregulation
of a number of human genes, indicating that expression of
one meiosis-specific epigenetic regulator can alter the transcrip-
tional landscape of human cells (Altemose et al., 2017). This
opens up a number of possibilities in terms of transcriptional
deregulation in cancers by single germ line/meiotic regulatory
gene.
However, new evidence has recently emerged to suggest a link
between meiotic recombination hot spots and genome stability
(Houle et al., 2018; Kaiser & Semple, 2018). PRDM9 has an affin-
ity for specific genomic sequences mediated by the PRDM9 zinc
finger domain (Grey et al., 2018; Paigen & Petkov, 2018)
(Fig. 2A). Analysis of these binding sites in human cancers indi-
cates that these are associated with sites of genome instability in
cancers (Houle et al., 2018; Kaiser & Semple, 2018). Intuitively,
this might suggest that they are causing a SPO11-TOPOVIBL-
mediated break that becomes the site for chromosomal instabili-




























Figure 2 Schematic of the initiation of meiotic inter-homologue recombination at hot spot loci. (A) Chromatin is specifically marked by the hot spot activa-
tor PRDM9. PRDM9 is a histone methyltransferase that recognizes specific DNA sequence motifs via a zinc finger domain (ZFD). Association with hot spot
motifs is followed by local methylation of histones to ‘open’ the chromatin making the DNA accessible to double-strand break (DSB) mediators. (B) An atyp-
ical topoisomerase-like complex (SPO11-TOPIVIBL) associates with the DNA, and the SPO11 moiety introduces a programmed DSB. (C–D) SPO11 remains
covalently bound to each 50 end of the DSB site. The 50 end covalently bound to SPO11 is processed away exposing single-stranded (ss) DNA with a free 30
end. (D–E) The 30 ssDNA ends associate with the recombinases RAD51 and DMC1, the latter being meiosis-specific. Via interaction with a number of factors,
such as HOP2-MND1, the recombinases (RAD51/DMC1) mediate inter-chromatid recombination with a meiosis-specific inter-homologue bias. Subsequent
processing results in the stabilization of these early inter-homologue intermediates, and a bivalent is formed (see B–D in Fig. 1).
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meiosis-specific factors (e.g. SPO11 and PRDM9) to act in con-
cert to generate a break, which seems overly complex. An addi-
tional and possibly more plausible explanation is that PRDM9
generates chromatin regions that become more fragile for other
reasons, such as causing unscheduled barriers to DNA replica-
tion which are known to be major initiators of genome instability
during oncogenesis (Blumenfeld et al., 2017; Zhang et al., 2018).
Exactly what the mechanism of oncogenic PRDM9 is remains
open to experimental scrutiny, but another feature to consider is
the possibility that this serves to assist tumour evolution by gar-
nering instability; it is widely accepted that tumours which have
greater propensity to undergo high rates of genomic change and
instability are more amenable to evolving therapeutic resistance
(Sansregret et al., 2018). Whilst it remains to be determined
whether enhanced tumour evolution is a feature of PRDM9 acti-
vation, there is evidence that activation of other meiotic genes
does indeed influence therapeutic evasion (see below).
Recently, another CT gene involved in SPO11-mediated
recombination regulation in mammals, TEX19, has been
reported to be required for maintaining the proliferative state of
cancer cells (Planells-Palop et al., 2017). The functional nature
of human TEX19 in cancer cells remains unknown, but the
TEX19 gene appears to be extensively activated in a range of can-
cer type (Feichtinger et al., 2012; Zhong et al., 2016). In the
mouse, there are two TEX19 orthologues, Tex19.1 and Tex19.2,
although the former paralogue is thought to be the functional
orthologue of human TEX19 (Kuntz et al., 2008; Ollinger et al.,
2008). Murine Tex19.1 appears to regulate a number of germ line
biological functions, most likely via a defined association with
the murine Ubr2 E3 ubiquitin ligase, and these include regula-
tion of LINE1 transposition and the initiation of SPO11 meiotic
recombination (Yang et al., 2010; Reichmann et al., 2013; Tara-
bay et al., 2013; Crichton et al., 2017, 2018; MacLennan et al.,
2017). TEX19 is mammalian-specific and so the D. melanogaster
l(3)mbt tumour studies do not shed any light on whether TEX19
is required early in the oncogenic programme, as well as being
required to maintain the proliferative status of cancer cells,
although preliminary analysis of human tumour progression
arrays suggests that it is activated early in the oncogenic pro-
gramme (Planells-Palop et al., 2017).
Meiosis I higher order chromosome modulators in cancers
Synapsis in meiosis I is marked by the formation of a pro-
teinaceous, ladder-like structure known as the synaptonemal
complex (SC), which interconnects homologous chromosomes
(Cahoon & Hawley, 2016) (Fig. 1C). Whilst the exact role of the
SC remains unclear, it is thought to modulate crossover control,
although it is not obligate, as some eukaryotes can mediate a
reductional meiosis I, with crossing over, in the absence of a
bona fide SC (Zickler & Kleckner, 1999). The formation of the
SC is mediated by proteinaceous axial structures, which
develop on sister chromatid pairs. Axial components include
SYCP3, the presence of which is frequently used as a molecular
marker for meiotic progression in GC tumours (for example,
see Jørgensen & Rajpert-De Meyts, 2014). The linear axial struc-
tures formed on each homologue come together via the devel-
opment of a central cross-linking structure containing the
conserved SYCP1 proteins to form the mature SC (Cahoon &
Hawley, 2016). In addition to axial structural components, such
as SYCP3, other factors are required to ensure that inter-
homologue recombination and SC formation are correctly
orchestrated, such as the HORMA domain protein HORMAD,
which also associates with the axis (Wojtasz et al., 2009; Shin
et al., 2010; Daniel et al., 2011).
Recent studies have demonstrated that both SYCP3 and HOR-
MAD1 can potentially provide oncogenic function and have the
capacity to do so outside the context of a full meiotic pro-
gramme. Given this, it is important to view GC tumour biology
in the full light of the capabilities of these meiotic proteins (see
below). SCYP3 produced outside the meiotic context has been
shown to disrupt the activity of the tumour-suppressing recom-
bination regulator BRCA2 and can modulate the strand invasion
capabilities of both the RAD51 and DMC1 (meiosis-specific)
recombinases that drive homologous recombination (Hosoya
et al., 2011; Kobayashi et al., 2017) (Fig. 3). Overexpression of
SCYP3 can also drive ploidy changes (Hosoya et al., 2011), and,
coincidently, ploidy changes are a key feature of a number of GC
tumours (for example, see Jørgensen et al., 1997). Aberrant
SYCP3 expression has also been associated with a distinct range
of cancers, and it can serve as a prognostic marker in both cervi-
cal and non-small-cell lung cancers (Chung et al., 2013; Cho
et al., 2014a; Kitano et al., 2017).
Additionally, important roles for HORMAD1 in controlling
oncogenic recombination pathways and therapeutic resistance
have emerged (Watkins et al., 2015; Gao et al., 2018; Nichols
et al., 2018; Wang et al., 2018). Two recent studies have demon-
strated that HORMAD1 expression is linked to poor prognosis
and drives genotoxic (including irradiation) and oxidative stress
resistance in lung adenocarcinomas (Gao et al., 2018; Nichols
et al., 2018). It is postulated that this is mediated by HORMAD1
promoting efficient re-sectioning of DSBs, making the repair of
therapeutic-induced damage more effective in cancer cells, a
process that could potentially give these cells a greater evolu-
tionary capacity. Consistent with this, HORMAD1 has also been
implicated in resistance to the poly-ADP ribose polymerase
(PARP) inhibitor rucaparib in basal-like breast cancers (Wang
et al., 2018). PARP inhibitors block the efficient repair of nicks
in double-stranded DNA ultimately leading to the formation of
more DSBs; in cancer cells with deficiencies in DSB repair, such
as BRCA2-negative cells, they become sensitive to rucaparib as
it is synthetically lethal with unrepaired DSBs (due to BRCA2
deficiency, for example). It is proposed that HORMAD1 medi-
ates rucaparib resistance by activating a distinct DSB repair
pathway that suppresses the synthetic lethality of rucaparib
and failed DSB repair. Indeed, Watkins et al. (2015), who first
demonstrated a recombination-associated function for HOR-
MAD1 in cancer cells, have postulated that aberrant expression
of HORMAD1 disrupts the normal homologous recombination
repair pathway driven by the recombinase RAD51 resulting in a
preference for a distinct DSB repair pathway, one that makes
triple-negative breast cancer cells expressing HORMAD1 more
responsive to platinum-based chemotherapy. Consistent with
this, the use of PARP inhibitors on ovarian cancer stem cells
induces foci of the meiosis-specific RAD51 recombinase par-
alogue, DMC1 (Bellio et al., 2019). This could suggest that PARP
inhibition induces an alternative homologous recombination
pathway which is dependent on activation of meiotic homolo-
gous recombination mediators replacing the loss of somatic
repair pathways and overriding the synthetic lethality caused by
PARP inhibition.
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In meiosis I, HORMAD1 is thought to ensure that DSBs are
amenable to driving meiotic homologous recombination, a key
feature of which is that it is biased down an inter-homologue
route, rather than an inter-sister route. This is mediated by a
number of meiosis-specific factors including two factors,
MND1-HOP2 (Tsubouchi & Roeder, 2002; Chen et al., 2004). The
first solid evidence that testis-specific regulators of meiosis-spe-
cific recombination could contribute to oncogenesis came from
the finding that these two factors could drive the ALT (alterna-
tive lengthening of telomeres) mechanism in cancer cells
(Arnoult & Karlseder, 2014; Cho et al., 2014b). To acquire the
potential to become proliferative immortal, cancer cells must
overcome the fact that telomeres become shorter each cell divi-
sion due to the majority of somatic cells being deficient in active
telomerase. Cancer cells not only can re-activate telomerase, but
also can initiate an ALT mechanism in the absence of this (De
Vitis et al., 2018). ALT requires a recombination-like mechanism
to recognize the telomere end as a DSB and mediate the strand
invasion of the end into a non-homologous chromosome end;
this strand invasion permits the initiation of a break-induced
DNA replication process to use the invaded non-homologue
telomeric DNA as a replicative template for the invading telom-
ere to elongate (Dilley et al., 2016). A key enabler in this pathway
is the need to bring non-homologous ends into close proximity.
It transpires that this enabler function is mediated by MND1-
HOP2 (Cho et al., 2014b). Not only was this the first clear
demonstration of meiotic factors functioning in oncogenesis,
but also the first example that reveals meiotic factors as poten-
tially highly specific therapeutic targets for cancers.
The meiotic cohesins in cancer
Chromosome regulation in both mitosis and meiosis is depen-
dent upon the cohesin complex. In mitotically dividing cells, this
complex serves to hold sister chromatids together following S
phase through to the point at which the complex, and thus inter-
sister cohesion, is synchronously disrupted during the meta-
phase-to-anaphase transition, permitting the equational segre-
gation of sister chromatids to opposing cellular poles in
preparation for cytokinesis (Ishiguro, 2018). In addition to this
role in sister chromatid cohesion, the complex also plays other
fundamental roles, including functions in DSB repair and tran-
scriptional regulation (Zhu & Wang, 2018). The cohesin complex
forms a ring-like structure which is thought to encircle both sis-
ter chromatids to mediate their cohesion and other functions
(Rankin & Dawson, 2016). In meiosis, cohesin complexes can be
distinguished from the mitotic cohesin complex as there are
meiosis-specific paralogues of some of the cohesin proteins that
can replace their mitotic counterparts (Ishiguro, 2018). Given
that meiotic cohesin complex mediates some very specialized
meiosis-specific functions, this interchangeability for cohesin
subunits generates a potential weakness in the mitotic–meiotic
regulatory interphase, as production of meiosis-specific cohesin
subunits in mitotic cells could readily impose oncogenic meio-
sis-like functions on cells. One of the more prominent cohesin
subunits that appears to be restricted to meiotic cells in many
eukaryotes is REC8, one of the two paralogous counterparts to
the RAD21 mitotic cohesin, RAD21L being the other (Ishiguro,
2018). REC8 not only is essential for inter-homologue meiotic
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Figure 3 Model of an example of a meiosis-specific recombination regulator altering genome dynamics in a non-meiotic cell: SYCP3 disruption of BRCA2
homologous recombination function. BRCA2 is required to facilitate the loading of the RAD51 recombinase, which is required for the strand invasion step of
inter-sister chromatid DNA double-strand break (DSB) repair in somatic, non-meiotic cells. A normal cellular response to a DSB requires RNA polymerase II
to mediate the de novo transcription of a damage-inducible long non-coding RNA (magenta strand) at the site of the DSB. This assists the resectioning of
the DSB to expose single-stranded (ss) DNA with a free 30 end and the recruitment of a cluster of end-processing factors, including BRCA2 and RNase H2,
the latter processing the RNA:DNA hybrid generated by RNA polymerase II to permit RAD51 loading onto the ssDNA end. BRCA2 functions to assist the
loading of the RAD51 recombination onto ssDNA and prevents aberrant loading onto double-stranded DNA. Under normal circumstances, effective RAD51
loading facilitates the next stages in DSB repair. However, when the meiotic factor SYCP3 is present and active, it associates with BRCA2, inhibiting its
RAD51 regulatory capability, disrupting normal DSB repair and potentially resulting in oncogenic genome instability, including aberrant repair partner
choice. Adapted from Hosoya et al. (2011).
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centromere monopolarity in meiosis I, which is essential to
ensure sister centromeres orientate to the same pole to drive the
reductional segregation. To impose monopolarity onto sister
centromeres in mitotically dividing cells could result in unipar-
ent disomy (UPD). Recent seminal work has demonstrated that
expression of a single meiotic cohesin subunit could indeed
drive high frequencies of UPD in mitotically dividing cells (Folco
et al., 2017). This work was carried out in the model organism
Schizosaccharomyces pombe (fission yeast) and serves to irrefu-
tably demonstrate the potential for imposition of meiotic cohe-
sin function in mitotic cells by aberrant expression of only a
single meiotic cohesin gene. In humans, this picture is less clear
as expression of the human REC8 gene does not appear to be
restricted to the testes (Feichtinger et al., 2012; Uhlen et al.,
2015), and indeed, there appears to be REC8 protein present in a
range of non-germ line somatic tissues (Uhlen et al., 2015).
Clearly, this REC8 does not normally drive UPD in healthy
human somatic cells, but these cells might be more readily
primed to switch to a meiosis-like function by as yet unknown
cues. Interestingly, REC8 does not appear to be incorporated
into mitotic cohesin complex in HEK293 cells unless another
meiosis-specific cohesion subunit, STAG3, is activated (Wolf
et al., 2018); so, potentially in human somatic cells REC8 meiotic
function becomes activated by the aberrant expression of other
meiotic-specific genes. Importantly, a reported feature of some
female GC cancers is homozygosity, postulated to be caused by
a failure of meiosis II or endoreduplication (Kato et al., 2018).
However, another possibility to be considered is that this is dri-
ven by UPD caused by sister centromeres taking on a meiosis
I-like monopolar configuration, possibly mediated by a meiosis-
specific function of REC8 being activated.
Despite REC8 appearing to be present in normal somatic tis-
sues, oncogenic activity has been ascribed to it. This includes
inference of a pseudomeiotic role for REC8 in endoploid cells
induced after ionizing irradiation (Erenpreisa et al., 2009) and
the finding that REC8 might be a tumour suppressor required to
inhibit the epithelial-to-mesenchymal transition in gastric can-
cers, possibly via a transcriptional regulation function (Yu et al.,
2017; Zhao et al., 2018).
Other meiosis-specific cohesin subunits, which have gene
expression tightly restricted to the testis in healthy humans,
are STAG3, SMC1b and RAD21L, the latter being another
RAD21/REC8 paralogue (Ishiguro, 2018). The corresponding
genes encoding these cohesins have been found to be activated
in some cancers, and overexpression of RAD21L in murine pri-
mary fibroblasts induces increased adjacency of homologous
chromosomes (Feichtinger et al., 2012; Rong et al., 2017). This
could help to facilitate oncogenic drivers such as ALT (see
above) and induction of loss of heterozygosity via homologous
recombination-mediated repair of DSBs via an inter-homolo-
gue route, suggesting that RAD21L expression could be onco-
genic. STAG3 levels have also been linked to resistance of
inhibition of the BRAF oncogene activity in melanoma (Shen
et al., 2016). The mechanism of this is unknown, but it is
reduced levels of STAG3 that are associated with resistance,
suggesting that STAG3 expression is a sensitizer, which sug-
gests elevating expression of a meiotic cohesin gene is a dis-
tinct therapeutic avenue in combination with BRAF inhibition
(Shen et al., 2016).
MEIOTIC FACTORS IN TESTICULAR GERM CELL
TUMOURS: MEIOSIS OR PSEUDOMEIOTIC ACTIVATION?
During embryonic development, PGCs migrate to the genital
ridge and enter the developing gonad, where they are directed
towards alternate pathways to differentiate into either oogonia
or spermatogonia (Jørgensen & Rajpert-De Meyts, 2014). This
either leads to entering meiosis in the foetal ovaries or leads to
the inhibition of meiosis initiation in the testes (Spiller & Bowles,
2015). The switch between mitosis and meiosis is a fundamental
and tightly controlled feature that occurs during germ cell devel-
opment, and even though it has not caught much attention of
GC tumour research, dysregulation of meiosis is believed to play
a role in GC tumour development (Jørgensen et al., 2013; Lanza
& Heaney, 2017).
Testicular germ cell tumours (TGCTs) are currently classified
into tumours that are derived from germ cell neoplasia in situ
(GCNIS, type II) and into those that are not (non-GCNIS, types I
and III) (Williamson et al., 2017). The non-GCNIS tumours are
subdivided into type I (teratoma and yolk sac tumour) and type
III (spermatocytic tumours) malignancies. GCNIS-derived, type
II tumours can be divided into two main histologic types, semi-
nomatous and non-seminomatous TGCTs, with non-seminoma-
tous types further grouped into embryonal carcinoma, yolk sac
tumour, teratoma and choriocarcinoma (Looijenga & Ooster-
huis, 2002; Williamson et al., 2017). TGCTs are not believed to
derive from a mature germ cell but rather to arise from PGCs
(Oosterhuis & Looijenga, 2005) and hence have their origin dur-
ing embryogenesis (Pierpont et al., 2017). A current tumour evo-
lution model suggests that non-GCNIS-derived, type I GC
tumours arise in the early stages of germ cell development dur-
ing PGC migration and proliferation, whereas GCNIS-derived
tumours are preceded by GCNIS cells that originate from gona-
dal PGCs (Cheng et al., 2018; Pierce et al., 2018). During germ
line development, PGCs undergo extensive epigenetic repro-
gramming, including modification of histone marks and erasure
of imprinting, which is thought to prepare the cells for differenti-
ation (Sato et al., 2003; Seki et al., 2005; Kristensen et al., 2013;
Hill et al., 2018). Consistent with the suggestion that the cell of
origin for type I neoplasms is of earlier stage, the type I GC
tumours have been found to be partially imprinted and type II
seminomas resemble gonadal PGCs in their erased DNA methy-
lation pattern (Ross et al., 1999; Schneider et al., 2001; Shen
et al., 2018). Type II non-seminomatous TGCTs, however,
appear to have regained some methylation patterns (Shen et al.,
2018). Also, an investigation of genetic and epigenetic alterations
in paediatric GC tumours concluded that most studied tumours
derived from pre-meiotic PGCs and only in a few cases tumours
appear to have arisen from errors during meiosis (Ichikawa
et al., 2013), although the UPD observed in some of these
tumours could also be explained by aberrant development of
monopolar centromeres by activation of REC8, for example (see
above), and not by a meiotic error per se. Only the rare type III
malignancies originate from more mature post-natal cells
(although probably from cells transitioning from spermatogonia
to spermatocytes, which are still pre-meiotic cells) (Rajpert-De
Meyts et al., 2003; Giannoulatou et al., 2017).
Whilst the cells of origin for the various tumour types have
somewhat been pinpointed, it is not clear how these tumour
cells maintain a proliferative programme. In a normal
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developmental setting, PGCs at extragonadal sites as well as at
the developing ovaries enter meiosis (McLaren & Southee, 1997),
whereas entry into mitotic G1/G0 arrest occurs in the developing
testes; yet, germ cells of TGCT-susceptible mice were associated
with delayed entry into mitotic arrest and retention of pluripo-
tency (Heaney et al., 2012). Furthermore, it is thought that
GCNIS and tumour cells are not able to progress through meiotic
prophase I, as impaired meiotic competence has been observed
in cells with PGC characteristics derived from mouse embryonic
stem cells (Tedesco et al., 2011; Jørgensen et al., 2013). This
raises the question whether these cells are mitotic and proliferat-
ing or attempt to enter meiosis but fail to proceed and revert to
mitotic proliferation through a defective mitotic–meiotic switch,
rendering them sexually confused. Indeed, a study by Jørgensen
co-workers reported meiosis-inducing and meiosis-inhibiting
factors to be expressed simultaneously in GCNIS (Jørgensen
et al., 2013), supporting their suggestion of sexually confused
cells (Rajpert-De Meyts, 2006). Further support is provided by
the fact that patients with disorders of sex differentiation exhibit
a higher risk of developing GC tumours (Skakkebaek et al.,
2016). Yet another possibility is that most GC tumours derive
from pre-meiotic PGCs, in which meiotic factors are prematurely
and unscheduled activated through defects in gene regulatory
mechanisms as observed in other cancers, rather than through a
defect in the switching between the mitotic and meiotic modes.
As discussed in the previous section, many tumours exhibit
aberrant expression of meiotic genes, in particular meiotic chro-
mosome regulators (and germ line genes in general), and onco-
genic links have been shown (McFarlane & Wakeman, 2017).
Either way, these cells do not or cannot initiate a full meiotic
programme, which is supported by the fact that varying and
contradicting expression patterns of meiotic genes in GC
tumours, cell lines and/or pre-malignant GCNIS have been
reported (Adamah et al., 2006; Jørgensen et al., 2013) (Fig. 4).
In relation to GC tumours, mostly meiotic entry regulator
genes have been studied, as the main focus was laid on meiotic
entry and the dysregulation of the mitotic–meiotic switch. Using
TCGA Research Network (http://cancergenome.nih.gov/) and
GTEx (Carithers et al., 2015; Keen & Moore, 2015) data extracted
through the GEPIA database (Tang et al., 2017), we assessed the
expression of a number of selected meiotic entry and meiotic
chromosome regulatory genes – hence genes expressed at vari-
ous stages of meiosis (Fig. 4). Interestingly, in TGCTs, full
expression of meiotic programme is clearly absent. Indeed, aber-
rant activation of meiotic genes from various stages appears to
have occurred, including the conflicting expression of meiosis-
inducing and meiosis-inhibiting factors, as reported before
(Jørgensen et al., 2013), but also the expression of meiotic chro-
mosome regulators as reported in other cancers (McFarlane &
Wakeman, 2017). In normal testis, however, expression of the
full meiotic programme can be observed, as this includes the
expression profiles of the full spectrum of pre-meiotic, meiotic
to post-meiotic cells. Recently, single-cell RNA-sequencing
experiments dissected the progression through meiosis (Chen
et al., 2018; Guo et al., 2018). According to Guo et al. (2018), the
selected meiotic genes aberrantly activated in TGCTs (Fig. 4)
should not be expressed at the same time.
Often markers for meiotic entry and meiosis (e.g. Spiller et al.,
2012) are used in studies but should be interpreted critically, par-
ticularly in a pathological setting, as they could represent an
unscheduled aberrant activation. For example, a study by Heaney
co-workers showed that only in rare cases, aberrant expression of
STRA8 induced entry into meiosis (Heaney et al., 2012) and is,
therefore, not a reliable marker for meiotic entry. Neither is
SYCP3 expression suitable as meiotic entry marker without inter-
rogating the functional activity of the SYCP3 protein, such as
chromosomal association and further formation of the SC, or
showing expression of genes in the associated meiotic gene clus-
ter (Heaney et al., 2012; Guo et al., 2018). Aberrant, unscheduled
SCYP3 expression outside the meiotic context has been shown in
other cancers (Chung et al., 2013; Cho et al., 2014a; Kitano et al.,
2017), where it has the potential to disrupt the activity of BRCA2,
potentially leading to the modulation of strand invasion capabili-
ties for recombinases (RAD51 and DMC1), which in turn drive
homologous recombination (Hosoya et al., 2011; Kobayashi et al.,
2017) (see above). Moreover, GC tumour research has been
mainly conducted in the mouse model and results should be cau-
tiously translated into a human setting. As mentioned previously,
the expression of the human REC8 gene, for example, does not
appear to be restricted to the testes (Feichtinger et al., 2012;
Uhlen et al., 2015), whereas it is indeed meiosis-specific in mice.
CONCLUDING REMARKS
Although solid tumours are characterized by heterogeneity,
cancer cells exhibit certain stereotypical functional capabilities,
such as growth and proliferative advantages, altered stress
response, invasion and metastasis, stimulated angiogenesis and
immune evasion (Fouad & Aanei, 2017). Nonetheless, how cancer
cells acquire such malignant characteristics remains very poorly
understood. One view is the embryologic theory of cancer, in
which cancer cells acquire embryo-like characteristics that would
explain the malignant features of cancer cells (Erenpreisa et al.,
2015). To some degree, this altered, or confused, developmental
model has been applied to interpret the expression of meiotic
genes in GC tumours. However, a range of cancers express
distinct subsets of genes from various otherwise restricted pro-
grammes such as meiotic/germ line and placental/embryogene-
sis-related to a varying degree (Jungbluth et al., 2007; Macaulay
et al., 2017; McFarlane & Wakeman, 2017; Bruggeman et al.,
2018; Costanzo et al., 2018). Hence, it could be speculated that
cancer cells acquire their malignant characteristics by aberrant
activation of a single gene or cluster of genes from one or more of
these programmes, and this occurs as it confers a selective advan-
tage on the cancer cell. Given that GC tumours arise from cells
intimately associated, both temporally and spatially, with the
meiotic developmental programme, current data do not permit a
clear delineation of why meiotic factors become activated in
some of these tumours and what role they play. The core question
of whether activation of these factors is linked to a developmental
confusion or positive selective activation (or both in distinct GC
tumour subtypes) appears to remain unaddressed. What is clear
is that an open view of the causes and consequences of meiotic
gene activation in GC tumours should be applied, as this may yet
reveal new and important aspects of GC tumour biology and new
therapeutic avenues.
MEETING COMMENTS
Niels Skakkebaek (Copenhagen, Denmark)
Are the meiosis-specific genes the same in males and females?
8 Andrology, 1–13 © 2019 American Society of Andrology and European Academy of Andrology
J. Feichtinger and R. J. McFarlane ANDROLOGY
Ramsay McFarlane
That is not known for certain but we assume that the core pro-
teins driving meiosis are the same in both sexes. However, there
are clearly differences between the sexes. One example is the
meiosis-specific protein SPO11, which mediates the formation
of meiosis-specific DNA double-strand break formation. In
males there is a specific variant of SPO11 which serves to medi-
ate XY inter chromosome associations in the pseudo autosomal
region. This function does not occur in females.
Ewa Rajpert-De Meyts (Copenhagen, Denmark)
Your studies are possibly related to the mechanisms of malig-
nant transformation of germ cells in males and females. The
fetal testis has an intricate mechanism with several backups to
prevent meiosis in germ cells, and this is regulated by their
somatic niche. Such regulation is absent in the fetal ovary where
meiosis occurs very early in life. The first stage of malignant
transformation of testicular germ cells is the formation of GCNIS
cells, and these cells often display premature aberrant partial
activation of meiosis. This would be expected to hamper growth
of such cells, but somehow it appears to help the abnormal cells
to survive and proliferate.
Ramsay McFarlane
Our initial thoughts were that premature activation of meiosis
must have negative consequences for the cell, and one might
assume that these would be anti-proliferative. I think, however,
that evidence from a range of cancers is showing that this view is
incorrect, as a number of meiotic genes can contribute onco-
genic functions to drive the proliferative state. How this relates
to germ line cancers remains an open question, in my view. Is
meiotic gene activation in germ line tumours a real attempt to
start a full meiotic program, as one might assume, given the nat-
ure of the cells? Or, is it simply due to activation of some meiotic
genes conferring a selective proliferative advantage (or some
combination of both)? I think this is an interesting and open
question and we should keep an open mind and look to generate
data to support or refute all options.
Leendert Looijenga (Rotterdam, the Netherlands)
In the NTERA-2 cell line with TEX19 knock down, did you
exclude that you were not only stopping proliferation, but per-
haps you were simply seeing cell differentiation?
Ramsay McFarlane
The NTERA-2 cell line is capable of undergoing differentia-
tion. Treatment with retinoic acid (RA) causes differentiation
along a neuronal lineage whereas HMBA treatment results in dif-
ferentiation down ill-defined lineages. We assessed cell morphol-
ogy changes and OCT4 expression following TEX19 knockdown
to address whether reduction in TEX19 levels triggered differenti-
ation; we could find no overt evidence that differentiation was
occurring. We used both HMBA and RA treated NTERA-2 cells as
controls. We also assessed what happens to TEX19 expression fol-
lowing differentiation induced by either RA or HMBA and found
that whilst OCT4 RNA levels were reduced quite quickly, TEX19
transcript levels stayed relatively high until complete differentia-
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Figure 4 Median expression of selected meiotic entry and meiotic chromo-
some regulatory genes in TCGA testicular germ cell cancers (TCGA-TGCT)
and GTEx normal testis (excluding capsule). Expression presented as log2
(transcripts per million + 1) values, which were extracted from the GEPIA
database (Tang et al., 2017) and plotted as heatmap in R (the range from
white to dark blue represents increasing expression values). ACTB was
included to show expression relative to a housekeeping gene. The TCGA-
TGCT data set is derived from 137 tumours [72 seminoma, 18 embryonal
carcinoma (EC), nine EC dominant, three mature teratoma, 10 mature ter-
atoma dominant, three immature teratoma dominant, five yolk sac
tumours, eight yolk sac tumours dominant and nine mixed tumours with
no dominant component (dominant > 60% presence of a given histology)]
(Shen et al., 2018). In TGCTs, full expression of meiotic programme is
clearly absent and aberrant activation of meiotic genes from various stages
appears to have occurred. In normal testis, however, expression of the full
meiotic programme can be observed, as this includes the expression profiles
of the full spectrum of pre-meiotic, meiotic to post-meiotic cells.
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Tim Oliver (London, UK)
You mentioned the BRCA2 gene, but have you looked at other
DNA repair genes such as TP53, which possibly explains the sen-
sitivity of seminoma to treatment?
Ramsay McFarlane
We have not studied BRCA2 directly in our experiments
although others have demonstrated that the meiosis-specific
SYCP3 protein can disrupt BRCA2 function. Whilst I’m not aware
that this has been studied extensively in germ line tumours,
SYCP3 does become expressed in germ line tumours, so disrup-
tion of BRCA2 activity in germ line tumours by meiotic factors is
an interesting possibility.
No we have not explored a relationship between other meiotic
factors and TP53 in germ line tumours.
Finn Edler von Eyben (Odense, Denmark)
In meiosis, there is a reduction of chromosomes from 2N to
1N, whereas, in testicular tumours there is duplication of chro-
mosomes from 2N to 4N. Can you speculate what is driving this
change?
Ramsay McFarlane
This is possible premeiotic replication without subsequent
segregation. Alternatively, there are other pathways that could
cause ploidy changes due to meiotic gene activation, not least of
which is the aberrant formation of mono polar centromeric
associations between sister centromeres by the activation of
REC8 cohesin function – this would explain the centromeric
homozygocity observed in some germ line tumours.
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